Varespladib
A phospholipase A2 inhibitor
| Varespladib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Varespladib is a small-molecule inhibitor of secretory phospholipase A2 (sPLA2), an enzyme involved in the inflammatory process and the production of pro-inflammatory lipid mediators. It has been investigated for its potential therapeutic effects in various inflammatory conditions and cardiovascular diseases.
Mechanism of action[edit | edit source]
Varespladib functions by inhibiting the activity of sPLA2, which is responsible for the hydrolysis of phospholipids, leading to the release of arachidonic acid. Arachidonic acid is a precursor for the synthesis of eicosanoids, which are potent mediators of inflammation. By blocking sPLA2, varespladib reduces the production of these inflammatory mediators.
Clinical research[edit | edit source]
Varespladib has been studied in clinical trials for its potential to reduce inflammation and improve outcomes in patients with acute coronary syndrome (ACS). However, results from these studies have been mixed, with some trials showing no significant benefit in reducing cardiovascular events.
In addition to cardiovascular research, varespladib has been explored as a treatment for snakebite envenomation. The inhibition of sPLA2 is thought to counteract the toxic effects of certain snake venoms, which often contain sPLA2 enzymes.
Chemical properties[edit | edit source]
Varespladib is available in different forms, including varespladib methyl and varespladib sodium. These forms differ in their chemical structure and solubility, which can affect their pharmacokinetic properties and clinical applications.
Related pages[edit | edit source]
References[edit | edit source]
Varespladib chemical structure
Varespladib methyl ester
Varespladib sodium salt
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
